Cargando…

SAT-132 Improvements Seen Among Clinicians Post-CME Related to Second-Line T2D Therapy

Background: As new data emerge comparing long-term treatment outcomes of different second-line T2D agents, clinicians need to understand new clinical considerations to improve patient care. We sought to determine if online education for primary care physicians (PCPs), diabetologists and endocrinolog...

Descripción completa

Detalles Bibliográficos
Autores principales: Larkin, Amy, Hanley, Kelly, Le, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551645/
http://dx.doi.org/10.1210/js.2019-SAT-132
_version_ 1783424425881763840
author Larkin, Amy
Hanley, Kelly
Le, Anne
author_facet Larkin, Amy
Hanley, Kelly
Le, Anne
author_sort Larkin, Amy
collection PubMed
description Background: As new data emerge comparing long-term treatment outcomes of different second-line T2D agents, clinicians need to understand new clinical considerations to improve patient care. We sought to determine if online education for primary care physicians (PCPs), diabetologists and endocrinologists, and nurses could improve clinical knowledge/competence regarding new data related to second-line therapy selection for T2D patients already on metformin. Methods: The CME activity was a 15 minute online video discussion of 2 expert faculty, with accompanying slides. Educational effect was assessed using a repeated pairs pre/post-assessment study design, consisting of knowledge-, competence-, and confidence-based questions. Chi-square tests assessed the extent of any difference between the pre- and post-assessment of whether knowledge/competence were demonstrated. P values were calculated as a measure of significance; P values <.05 being statistically significant. The activity launched April 24, 2018. Data were collected through May 30, 2018. Results: • Overall, 373 PCPs, 89 diabetologists and endocrinologists, and 776 nurses completed the study • A significant educational effect was achieved for PCPs (P<.0001), diabetologists and endocrinologists (P=.006), and nurses (P<.0001). • Identifying better long-term durability of glycemic control with DPP-4 inhibitors than SUs: 18% improvement among PCPs (P<.0001), 15% improvement (P =.0135) among diabetologists and endocrinologists, and 22% improvement (P<.0001) among nurses • Selecting a second-line T2D agent to minimize weight gain: 10% improvement among PCPs (P=.0002), 9% improvement (P =.0467) among diabetologists and endocrinologists, and 18% improvement (P<.0001) among nurses • Confidence in using DPP-4 inhibitors in their patients with T2D: 39% of PCPs, 28% of diabetologists and endocrinologists, and 45% of nurses demonstrated positive changes An ongoing educational gap identified by low post-assessment knowledge/competence was: • 27% of PCPs, 16% of diabetologists and endocrinologists, and 40% of nurses still demonstrate confusion on new data related to durability of second-line T2D treatment options Conclusion: This study demonstrates the success of a 15 minute online video discussion at improving knowledge, competence, and confidence of intensifying T2D regimens. Now that many more clinicians understand the importance of durability of T2D treatment, a case-based activity is recommended for data application and reinforcement.
format Online
Article
Text
id pubmed-6551645
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Endocrine Society
record_format MEDLINE/PubMed
spelling pubmed-65516452019-06-13 SAT-132 Improvements Seen Among Clinicians Post-CME Related to Second-Line T2D Therapy Larkin, Amy Hanley, Kelly Le, Anne J Endocr Soc Diabetes Mellitus and Glucose Metabolism Background: As new data emerge comparing long-term treatment outcomes of different second-line T2D agents, clinicians need to understand new clinical considerations to improve patient care. We sought to determine if online education for primary care physicians (PCPs), diabetologists and endocrinologists, and nurses could improve clinical knowledge/competence regarding new data related to second-line therapy selection for T2D patients already on metformin. Methods: The CME activity was a 15 minute online video discussion of 2 expert faculty, with accompanying slides. Educational effect was assessed using a repeated pairs pre/post-assessment study design, consisting of knowledge-, competence-, and confidence-based questions. Chi-square tests assessed the extent of any difference between the pre- and post-assessment of whether knowledge/competence were demonstrated. P values were calculated as a measure of significance; P values <.05 being statistically significant. The activity launched April 24, 2018. Data were collected through May 30, 2018. Results: • Overall, 373 PCPs, 89 diabetologists and endocrinologists, and 776 nurses completed the study • A significant educational effect was achieved for PCPs (P<.0001), diabetologists and endocrinologists (P=.006), and nurses (P<.0001). • Identifying better long-term durability of glycemic control with DPP-4 inhibitors than SUs: 18% improvement among PCPs (P<.0001), 15% improvement (P =.0135) among diabetologists and endocrinologists, and 22% improvement (P<.0001) among nurses • Selecting a second-line T2D agent to minimize weight gain: 10% improvement among PCPs (P=.0002), 9% improvement (P =.0467) among diabetologists and endocrinologists, and 18% improvement (P<.0001) among nurses • Confidence in using DPP-4 inhibitors in their patients with T2D: 39% of PCPs, 28% of diabetologists and endocrinologists, and 45% of nurses demonstrated positive changes An ongoing educational gap identified by low post-assessment knowledge/competence was: • 27% of PCPs, 16% of diabetologists and endocrinologists, and 40% of nurses still demonstrate confusion on new data related to durability of second-line T2D treatment options Conclusion: This study demonstrates the success of a 15 minute online video discussion at improving knowledge, competence, and confidence of intensifying T2D regimens. Now that many more clinicians understand the importance of durability of T2D treatment, a case-based activity is recommended for data application and reinforcement. Endocrine Society 2019-04-30 /pmc/articles/PMC6551645/ http://dx.doi.org/10.1210/js.2019-SAT-132 Text en Copyright © 2019 Endocrine Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Diabetes Mellitus and Glucose Metabolism
Larkin, Amy
Hanley, Kelly
Le, Anne
SAT-132 Improvements Seen Among Clinicians Post-CME Related to Second-Line T2D Therapy
title SAT-132 Improvements Seen Among Clinicians Post-CME Related to Second-Line T2D Therapy
title_full SAT-132 Improvements Seen Among Clinicians Post-CME Related to Second-Line T2D Therapy
title_fullStr SAT-132 Improvements Seen Among Clinicians Post-CME Related to Second-Line T2D Therapy
title_full_unstemmed SAT-132 Improvements Seen Among Clinicians Post-CME Related to Second-Line T2D Therapy
title_short SAT-132 Improvements Seen Among Clinicians Post-CME Related to Second-Line T2D Therapy
title_sort sat-132 improvements seen among clinicians post-cme related to second-line t2d therapy
topic Diabetes Mellitus and Glucose Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551645/
http://dx.doi.org/10.1210/js.2019-SAT-132
work_keys_str_mv AT larkinamy sat132improvementsseenamongclinicianspostcmerelatedtosecondlinet2dtherapy
AT hanleykelly sat132improvementsseenamongclinicianspostcmerelatedtosecondlinet2dtherapy
AT leanne sat132improvementsseenamongclinicianspostcmerelatedtosecondlinet2dtherapy